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Abstract
Background
Human tuberculosis (TB) is caused by seven phylogenetic lineages of the Mycobacterium
tuberculosis complex (MTBC), Lineage 1–7. Recent advances in rapid genotyping of MTBC
based on single nucleotide polymorphisms (SNP), allow for phylogenetically robust strain
classification, paving the way for defining genotype-phenotype relationships in clinical set-
tings. Such studies have revealed that, in addition to host and environmental factors, strain
variation in the MTBC influences the outcome of TB infection and disease. In Tanzania,
such molecular epidemiological studies of TB however are scarce in spite of a high TB
burden.
Methods and findings
Here we used SNP-typing to characterize a nationwide collection of 2,039 MTBC clinical iso-
lates representative of 1.6% of all new and retreatment TB cases notified in Tanzania during
2012 and 2013. Four lineages, namely Lineage 1–4 were identified within the study popula-
tion. The distribution and frequency of these lineages varied across regions but overall, Line-
age 4 was the most frequent (n = 866, 42.5%), followed by Lineage 3 (n = 681, 33.4%) and 1
(n = 336, 16.5%), with Lineage 2 being the least frequent (n = 92, 4.5%). We found Lineage
2 to be independently associated with female sex (adjusted odds ratio [aOR] 2.14; 95% con-
fidence interval [95% CI] 1.31 – 3.50, p = 0.002) and retreatment cases (aOR 1.67; 95% CI
0.95 – 2.84, p = 0. 065) in the study population. We found no associations between MTBC
lineage and patient age or HIV status. Our sublineage typing based on spacer oligotyping
on a subset of Lineage 1, 3 and 4 strains revealed the presence of mainly EAI, CAS and
LAM families. Finally, we detected low levels of multidrug resistant isolates among a subset
of 144 retreatment cases.
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Conclusions
This study provides novel insights into the MTBC lineages and the possible influence of
pathogen–related factors on the TB epidemic in Tanzania.
Introduction
Tuberculosis (TB) is the leading cause of mortality due to an infectious disease [1]. In 2017, an
estimated 10 million people developed TB globally, with 1.6 million dying of the disease. Tan-
zania is among the thirty high burden countries, with a national average TB notification rate of
129 cases per 100,000; however, some regions show higher notification rates [2]. Like in most
sub-Saharan African countries, the HIV epidemic contributes substantially to the high TB inci-
dence in Tanzania, where a-third of the TB patients are co-infected with HIV [2]. Contrarily,
drug-resistant TB is still low in this setting [3]. Other risk factors such as poverty also influence
the epidemiology of TB in Tanzania [4].
Transmission of TB occurs via infectious aerosols, where upon exposure individuals can
either clear the infection, develop active disease or remain latently infected [5]. The complex
dynamics of TB infection and disease are determined by the environment, the host and the
pathogen [6]. Seven main phylogenetic lineages of the Mycobacterium tuberculosis complex
(MTBC) (Lineage 1–7) cause TB in humans [7]. These lineages are phylogeographically dis-
tributed, partially reflecting human migration histories [8–10]. Genomic differences among
the MTBC strains translate into relevant biological and epidemiological phenotypes [11]. Epi-
demiologically speaking, these phenotypes are demonstrated by indicators such as transmis-
sion potential, disease severity and progression rates from infection to disease [12–15]. In
general, strains of the widely distributed lineages, Lineage 2 and 4 or “generalists”, appear to be
more virulent than those of the geographically restricted lineages, Lineage 5 and 6 or “special-
ists” [7,11].
Studying genotype-phenotype relationships requires understanding the genetic diversity of
MTBC clinical strains in a given clinical setting. In Tanzania, few studies have described the
genetic diversity of the MTBC [16–19]. These previous works used conventional genotyping
tools such as the spacer oligonucleotide typing (spoligotyping) technique and revealed the
presence of mainly the East African Indian (EAI), Central Asian (CAS) and Latin American
Mediterranean (LAM) spoligo families, and the Beijing family reported only at the lowest fre-
quencies. Based on phylogenetically robust techniques, which include single nucleotide poly-
morphisms (SNPs), the spoligo families correspond to Lineage 1, 3, 4 and 2, respectively.
These previous studies from Tanzania are limited as they only focused on few specific geo-
graphical locations on the country and only one study profiled MTBC on a countrywide scale
albeit with low sampling coverage [18]. Moreover, despite the invaluable contribution of tech-
niques like spoligotyping in the molecular epidemiology field, such techniques are suboptimal
for phylogenetically robust strain classification due to high rates of convergent evolution
[20,21].
In this study, we applied for the first time a robust SNP typing method to classify the largest
so far nationwide representative collection of clinical isolates to gain insights into unknown
patterns of MTBC diversity in different regions of Tanzania. Given that only few studies have
assessed and identified lineage-specific differences in clinical settings, we then looked for
potential associations between the MTBC lineages and the available clinical and epidemiologi-
cal characteristics of the patients in the study population.
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Material and methods
Ethics statement
The study was approved by the National Tuberculosis and Leprosy Programme and the ethical
clearance was provided by the National Institute for Medical Research of Tanzania (Dar es
Salaam, Tanzania). The data in this study were analyzed anonymously.
The National Tuberculosis and Leprosy Program routine drug surveillance
system
Our study was based on a nationwide convenience sample of sputum smear positive new and
retreatment TB cases diagnosed between 2012 and 2013 in Tanzania. The collection was
obtained via a platform established for routine TB drug resistance surveillance by the National
Tuberculosis Leprosy Program (NTLP) of Tanzania, covering health facilities in all geographi-
cal regions of the country. Briefly, smear positive sputa specimens from approximately 25% of
new TB cases and from all retreatment cases were obtained for the drug resistance surveillance.
To obtain 25% sputa from new cases each region was allocated four months per annum, where
the respective health facilities in the region submitted sputa samples to zonal reference labora-
tories for culture. The zonal laboratories include the Central Tuberculosis Reference Labora-
tory (CTRL) in Dar es Salaam, Bugando Medical Center (BMC) in Mwanza and Kilimanjaro
Christian Medical Center (KCMC) in Kilimanjaro, which serve the Coastal and Southern
zone, the Lake zone, and the Northern zone, respectively. Isolates from the two zonal laborato-
ries, BMC and KCMC were then sent to the CTRL for drug susceptibility testing (DST). For
this study we included all the isolates we could retrieve from the culture archives at the CTRL.
Study population and data collection
We included a total of 2,039 unique (single patient) culture-confirmed TB cases, each of whom
we could retrieve the respective culture isolate from the CTRL culture archives. This study
population represents 1.6% of all the estimated TB notified cases in the country between 2012
and 2013 (S1 Fig). We also obtained corresponding socio-demographic and clinical informa-
tion collected during patients’ consultation at the respective health facilities. The demographic
data collected included age, sex and geographical location of the patients, whereas clinical data
included HIV status and disease category (i.e., new case and retreatment case).
Processing of culture isolates
The smear positive sputa samples were cultured on Lo¨wenstein Jensen (LJ) growth medium
according to laboratory protocols. For this study, we included MTBC clinical isolates retrieved
from archived LJ media. We then prepared heat inactivated samples for the retrieved clinical
isolates by suspending MTBC colonies into 1ml sterile water and heat inactivate at 95˚C for
one hour.
Molecular genotyping
We then classified the MTBC clinical isolates into main phylogenetic lineages by TaqMan real-
time PCR according to standard protocols (Applied Biosystems, Carlsbad, USA) and as previ-
ously described [22]. Briefly, the TaqMan PCR uses fluorescently labeled allele-specific probes
for singleplex SNP-typing that are specific for each MTBC lineage. For comparisons, we also
performed 43-spacer spoligotyping on a membrane for a subset of representative MTBC clini-
cal strains following standard protocols [23], since spoligotyping is still widely used as a gold
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standard for genotyping in similar settings. We randomly selected 107 samples out of the 2,039
representative of three lineages, Lineage 1, 3 and 4. We excluded Lineage 2 strains for this anal-
ysis given that such strains almost exclusively belong to the Beijing family. The clinical strains
were assigned to spoligotype families using the online database SITVITWEB [24].
Drug resistance genotyping
We selected a subset of 144 clinical isolates from the 321 retreatment cases to perform molecu-
lar drug resistance testing. We used a previously described multiplex polymerase chain reac-
tion (PCR) to target the rifampicin resistance determining region of rpoB gene [25]. The PCR
assay targets both the tuberculous and non-tuberculous Mycobacteria (MTBC and NTMs,
respectively) rpoB gene, so we could also rule out the presence of non-tuberculous isolates in
our study sample using the assay. The amplified rpoB gene product was confirmed by electro-
phoresis on a 2% agarose gel and sent for Sanger sequencing. We analyzed the resulting
sequences by Staden software package [26] and using MTBC H37Rv rpoB gene as reference
sequence.
Statistical analysis
For statistical analysis, we applied descriptive statistics to delineate patients’ characteristics.
We used Chi-square or Fisher’s exact tests for assessment of differences between groups in cat-
egorical variables, whenever applicable. We used univariate and multivariate logistic regres-
sion models to assess for the association between MTBC lineages and patients’ clinical and
demographic characteristics. The associations were assessed for Lineage 2 compared to all
other lineages (Lineages 1, 3 and 4), adjusting for age, sex, disease category and HIV status. All
statistical analyses were performed in R 3.5.0 [27].
Results
Patients’ demographic and clinical characteristics
The patients’ demographic and clinical information in our study included age, sex, geographi-
cal location, HIV and disease category (new or retreatment case). Table 1 describes patients’
characteristics of the study population. The proportions of the observed and missing data for
the study population are summarized in S2 Fig.
Our study population consisted of TB patients ranging between the age of 2 and 89 years
with a median age of 28 years (interquartile range [IQR] 27–44). To further probe the age dis-
tribution in the study population, we categorized the TB patients into five different age groups
(Table 1). We detected approximately three-quarters of the TB cases to occur among the
“young age” and “early adult” age groups. Further, our findings show that about 1.0% of the
TB cases were pediatric cases (< 15 years).
Similar to other settings [1], we identified a higher proportion of male TB cases compared
to female TB cases. However, the male-to-female ratio observed in our study population was
higher than the national estimates for the two years of sampling (2.2:1 vs., 1.4:1). The striking
gender imbalance among TB cases seems to peak at adolescence onwards and is less pro-
nounced among pediatric TB cases (S1 Table). Additionally, a-third (32.2%, 517/1604) of the
TB cases with available HIV status were HIV co-infected. In contrast, TB/HIV co-infected
cases were more likely to be female (44.5%, CI 38.3–50.7% vs., 25.8%, 95% CI 20.6–31.0%)
which is consistent with HIV being generally more prevalent in females than males in Tanza-
nia [28]. We found that our study population comprised 16.1% (321/2000) of TB retreatment
cases, which was four-fold higher than the overall countrywide notifications [29]. Finally,
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more than half (51.6%, 1029/1996) of the TB patients in our study population were diagnosed
in the Coastal zone of Tanzania and about 40% were either diagnosed in the Lake and North-
ern zones. In addition to higher TB notification rates, the three former mentioned geographi-
cal zones contain the country’s zonal TB reference laboratories. The remaining 10% of the
patients were diagnosed in any of the remaining four geographical zones of Tanzania.
Table 1. Clinical and demographic characteristics of the TB cases.
Characteristics Valid Proportion % Total (%)
n = 2,039
Age, median (IQR)
35 (27–44)
Age groups (years)
Child age (< 15) 9.9 20 (1.0)
Young age (15–24) 29.7 312 (15.3)
Early adult (25–44) 48.0 1170 (57.4)
Late adult (45–64) 10.0 379 (18.6)
Old age (> 65) 2.5 73 (3.6)
Not available 85 (4.2)
total n = 1,954
Sex
Female 32.4 645 (31.6)
Male 67.6 1346 (66.0)
Not available 48 (2.4)
total n = 1,991
HIV status
Negative 67.7 1086 (53.3)
Positive 32.2 517 (25.4)
Indeterminate 0.06 1 (0.1)
Not available 435 (21.3)
total n = 1,604
Patient category
New case 84.0 1,679 (82.3)
Retreatment 16.1 321 (15.7)
Not available 39 (1.9)
total n = 2,000
Geographical zone
Central 1.1 22 (1.1)
Coastal 51.6 1,029 (50.5)
Lake 17.9 358 (17.6)
Northern 20.2 403 (19.8)
S. Highlands 8.1 162 (8.0)
Western 0.5 10 (0.5)
Zanzibar 0.6 12 (0.6)
Not available 43 (2.1)
total n = 1,996
IQR, interquartile range; valid proportion, proportion excluding missing values; Total n, all values including NA (not
available).
https://doi.org/10.1371/journal.pone.0206334.t001
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Main MTBC lineages in Tanzania
Using SNP-typing, we detected four of the seven known MTBC lineages (Fig 1), albeit at vary-
ing proportions. In our study population, Lineage 4 and Lineage 3 were the most frequent
(866, 42.5% and 681, 33.4%, respectively) followed by Lineage 1 (336, 16.5%). Lineage 2 was
the least frequent (92, 4.5%). The remaining 64 clinical isolates (3.1%) could not be assigned to
any of the MTBC lineages possibly because there was insufficient amount of DNA in the sam-
ples (below the detection limit). Of the seven geographical zones, four (Coastal, Northern,
Lake and Southern Highlands) were highly represented with more than 100 clinical strains
each (Table 2). The distribution of the MTBC lineages varied within the geographical zones
(Fig 1 and S3 Fig). Our findings reveal that Lineage 1 strains were more frequent in the Lake
zone compared to the overall average frequency (20.9% vs. 16.8%), whereas the frequency of
Lineage 3 in this zone was lower (27.6% vs. 34.3%) compared to other geographical zones. By
Fig 1. MTBC lineages in Tanzania. A. MTBC lineage classification of 2,039 nationwide clinical strains. B. MTBC lineage frequencies and geographical distribution in
Tanzania.
https://doi.org/10.1371/journal.pone.0206334.g001
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contrast, Lineage 4 was the most predominant in all geographical zones and showed relatively
similar frequencies across the zones.
Sublineage classification
After we detected four main MTBC lineages, we next explored the respective subfamilies on a
subset of Lineage 1, 3 and 4 strains using spoligotyping. Lineage 2 strains were excluded from
this analysis since the global strains almost exclusively belong to one spoligotype family, Bei-
jing with almost identical fingerprint pattern. We identified 24 spoligotypes (SITs; Spoligotype
International Type) among the 107 clinical strains analyzed (S2 Table). Twenty six (24.3%) of
the spoligo patterns had not been previously reported in the SITVITWEB database and there-
fore we assigned them as orphan spoligotypes. Several spoligotypes were identified within each
of the three lineages. EAI5 was the common spoligotype among the Lineage 1 and CAS1_Kili
spoligotype among the Lineage 3 strains. Within Lineage 4 strains, LAM, T, and H families
were detected and the LAM subfamily, particularly LAM_ZWE was the most frequent.
Association between lineage and patients’ characteristics
Having described the circulating main lineages of the MTBC we then assessed the relationship
between these lineages and patients’ characteristics in the study population (Table 3). We
detected a higher proportion of female sex among TB patients infected with Lineage 2 (52.1%)
compared to those infected with the other three lineages (range from 31% to 34.5%, p = 0.009).
Moreover, we observed that retreatment cases were frequently infected with Lineage 2 strains
(26.8%), which was twofold higher compared to Lineage 1 and 4 strains (p< 0.001). We found
no evidence for association between lineages and patients’ characteristics such as age and HIV
status (Table 3).
Lineage 2 has previously been associated with retreatment cases, drug resistance and lately
also with female sex [15,25]. We therefore investigated if similar associations exist in our study
population using a subset of TB cases with complete clinical and demographic information
(n = 1,535). To assess these associations we performed logistic regression analyses comparing
Lineage 2 to all other lineages pooled together (Table 4). Our analyses revealed Lineage 2 to be
independently associated with female sex (adjusted odds ratio [aOR] 2.14; 95% confidence
interval [95% CI] 1.31 – 3.50, p = 0.002) and retreatment cases (aOR 1.67; 95% CI 0.95 – 2.84,
p = 0.065). We did not detect any association between the lineages and patients’ age and the
HIV status.
Table 2. MTBC lineage distribution across geographical regions in Tanzania.
Geographical Zone Lineage Total
L1 (%) L2 (%) L3 (%) L4 (%)
Central 8 (38.1 ) 2 (9.5 ) 4 (19 ) 7 (33.3 ) 21
Coastal 168 (16.8 ) 50 (5 ) 350 (35 ) 432 (43.2 ) 1,000
Lake 72 (20.9 ) 12 (3.5 ) 95 (27.6 ) 165 (48 ) 344
Northern 52 (13.3 ) 22 (5.6 ) 145 (37 ) 173 (44.1 ) 392
S. Highlands 27 (16.9 ) 4 (2.5 ) 60 (37.5 ) 69 (43.1 ) 160
Western 0 (0 ) 1 (10 ) 4 (40 ) 5 (50 ) 10
Zanzibar 2 (18.2 ) 0 (0 ) 5 (45.5 ) 4 (36.4 ) 11
Total 329 (17 ) 91 (4.7 ) 663 (34.2 ) 855 (44.1 ) 1,938
L1, Lineage 1; L2, Lineage 2; L3, Lineage 3; L4, Lineage 4
https://doi.org/10.1371/journal.pone.0206334.t002
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Mutations within rpoB gene in retreatment cases
To investigate whether drug resistance was linked to a particular lineage, we included in total
144 out of 321 retreatment cases for drug resistance genotyping of the rpoB gene that confers
resistance to rifampicin. Out of these, 112 (77.8%) had no mutations compared to the H37Rv
reference gene and 15 (10.4%) contained at least one mutation, either synonymous (3/15) or
non-synonymous (12/15) (S4 Fig and S3 Table). We could not determine mutation status in
the rpoB gene of 17 (11.8%) retreatment cases due to PCR and sequencing failure. Among the
12 strains detected with non-synonymous rpoB mutations, five belonged to Lineage 2, four to
Lineage 4, and three to Lineage 3 (S4 Table). Table 5 summarizes the non-synonymous rpoB
mutations detected.
Discussion
In this study, we classified the countrywide collection of 2,039 MTBC isolates representing
1.6% of all smear positive new and retreatment TB cases notified during 2012 and 2013 in
Table 3. Frequency distribution of MTBC main lineages across patients’ characteristic groups.
Patient characteristics Lineage
L1, n (%) L2, n (%) L3, n (%) L4, n (%)
Age group
Child age (< 15) 2 (0.7) 0 (0) 7 (1.3) 8 (1.2)
Young age (15–24) 44 (16.2) 10 (13.9) 79 (14.9) 112 (16.9)
Early adult (25–44) 156 (57.4) 44 (61.1) 336 (63.5) 378 (57.1)
Late adult (45–64) 57 (21.0) 15 (20.8) 85 (16.1) 140 (21.1)
Old age (> 65) 13 (4.8) 3 (4.2) 22 (4.2) 24 (3.6)
Sex
Female 85 (31.3) 37 (51.4) 184 (34.8) 223 (33.7)
Male 187 (68.8) 35 (48.6) 345 (65.2) 439 (66.3)
HIV status
Negative 184 (67.6) 45 (62.5) 349 (66.0) 459 (69.3)
Positive 88 (32.4) 27 (37.5) 180 (34.0) 203 (30.7)
Patient category
New case 235 (86.4) 53 (76.6) 405 (76.6) 560 (84.6)
Retreatment 37 (13.6) 19 (26.4) 124 (23.4) 102 (15.4)
Total 272 (17.7) 72 (4.7) 529 (34.4) 662 (43.2)
L1, Lineage 1; L2, Lineage 2; L3, Lineage 3; L4, Lineage 4
https://doi.org/10.1371/journal.pone.0206334.t003
Table 4. Associations of patients’ clinical and demographic characteristics with MTBC Lineage 2 (n = 72) compared to all other lineages (n = 1,463).
Patient characteristics Lineage 2 Unadjusted Adjusted
n (%) OR (95% CI) p value OR (95% CI) p value
Age, median (IQR) 35 (28–44) 0.99 (0.97 – 1.01) 0.329
Female sex 37 (51.4) 2.09 (1.30–3.36) 0.002 2.14 (1.31 – 3.50) 0.002
Retreatment case 19 (26.4) 1.64 (0.93–2.76) 0.075 1.67 (0.95 – 2.84) 0.065
HIV positive 27 (37.5) 0.79 (0.49–1.31) 0.349 0.90 (0.55–1.51) 0.91
Observations 1,535 1,535
IQR, Interquartile range; OR, Odds ratio; 95% CI, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0206334.t004
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Tanzania. Our findings show that the MTBC strains among the study population are diverse,
comprising four main phylogenetic lineages (Lineage 1–4) which occur throughout the coun-
try. Specifically, we found that Lineage 4 was the most frequent, followed by Lineage 3 and 1.
Despite Lineage 2’s recent global dissemination [13], it was the least frequent in our study pop-
ulation. Finally, our analysis on the relationship between MTBC lineages and patients’ charac-
teristics revealed associations of Lineage 2 with female sex and retreatment TB cases included
in the study population.
Among the 7 human–adapted MTBC lineages, Lineage 4 is the most broadly distributed
and occurs at high frequencies in Europe, the Americas and Africa [24,34]. In our study, we
observe that TB epidemics in Tanzania are also predominated by Lineage 4, which is regarded
as the most successful of MTBC lineages [34]. In general, the wide geographical range of Line-
age 4 is postulated to be driven by a combination of its enhanced virulence, high rates of
human migration linked to its spread and ultimately its ability to infect different human popu-
lation backgrounds [34,35]. In contrast, Lineage 1 and 3 are known to be mainly confined to
the rim of the Indian Ocean [7], which is consistent with our observation that nearly 50% of
the MTBC strains included in the study belong to these two lineages. This high frequency of
Lineage 1 and 3 likely reflects the long-term migrations between Eastern Africa and the Indian
subcontinent [36]. In addition, the distribution and frequency of Lineage 1 and 3 in the main-
land subset did not vary from that of the coastal region, suggesting spread via internal migra-
tions. Lineage 1 was proposed to have evolved in East Africa prior disseminating out of the
continent [10]. Based on this, one might expect higher frequencies of Lineage 1 in the region.
Instead, the so called “modern” (TbD1−) lineages (4 and 3 in this case) could be dominating in
Tanzania despite presumably being introduced into the African continent only after the first
European contact [34,37]. This perhaps illustrates the ability of “modern” lineages to thrive in
co-existence with the pre-existing “ancient” (TbD1+) lineages such as Lineage 1 in our case,
perhaps because of the comparably higher virulence [14,38]. The neighboring countries of
Tanzania on the other hand show comparable MTBC lineage composition to our study
[39,40], suggesting common demographic histories and ongoing exchanges that resulted into
distinct MTBC populations. Our findings would suggest the frequency of Lineage 2–Beijing in
Tanzania, like in most parts of the continent except for South Africa [39,40] to be relatively
low, despite the long-standing African-Asian contacts [40]. Evidence from recent studies show
that Lineage 2–Beijing was only recently introduced into Africa [13,41].
The burden of TB disease is generally higher in males [1,42], rendering male sex as a poten-
tial risk factor for TB. Furthermore, the male bias among TB patients is also observed in
Table 5. Non-synonymous mutations detected on the rpoB gene among retreatment cases.
Lineage rpoB mutation Amino acid change n Source
L2 A1198G;C1349T T400A;S450L 1 [30,31]
C1333T H445Y 1 [31]
C1349T S450L 3 [31]
L3 T1289C L430P 1 [32]
C1333T H445Y 1 [31]
C1349T S450L 1 [31]
L4 A1334T H445L 1 [31]
G1333C H445D 1 [31]
C1294G;A1442G Q432E;E481A 1 [32,33]
C1333T H445Y 1 [31]
Total 12
https://doi.org/10.1371/journal.pone.0206334.t005
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settings with no obvious sex-based differences in health-seeking behavior [43]. Whilst we
show similar trends in this study, our findings reveal that the proportion of females was higher
among TB patients infected with Lineage 2. This finding is consistent with several other previ-
ous studies conducted in different settings [15,25,44]. Social and physiological factors predis-
posing males to higher risk of TB have been indicated [45]. On the one hand, these include
risk behaviors such as substance abuse (alcoholism, tobacco smoking) and gender specific
roles such as risk occupations (e.g., mining) that are male dominated and known to increase
the risk for TB. On the other hand, genetic makeup and sex hormones might contribute to the
differences in TB susceptibility among females and males, as epidemiological and experimental
studies have suggested female sex hormones to be protective [45]. These observations would
propose that the sex imbalance in TB emerges after the onset of puberty. Of note, we observe
less sex imbalance in “child” age group (<15 years) which also corroborates the national notifi-
cation rates [29]. However, this observation can be confounded by BCG vaccination which
might be most effective in this age group. Despite the high prevalence of HIV among young
females in sub-Saharan Africa [28] and HIV being the strongest risk factor for TB, TB burden
remains higher in males. While social and physiological aspects play an important role, find-
ings from this study and others previously conducted in Nepal and Vietnam [15,25] suggest
that bacterial factors could disrupt the trends towards male bias in TB, a finding which war-
rants further investigation. Our hypothesis is that because of higher virulence, Lineage 2
strains are able to overcome the resistance poised by female sex which could explain the less
pronounced sex imbalanced.
In addition to its association with female sex, we found that retreatment TB cases were
more likely infected with Lineage 2. A retreatment case in our study population represented
recurrent TB case either due to relapse or reinfection. We hypothesized that this observation
was possibly linked to drug resistance, given the previous reported association between Line-
age 2 and drug resistance [46]. However, we detected only 8.3% (12/144) of strains among the
retreatment subset tested to contain mutations conferring resistance to rifampicin, five of
which belonged to Lineage 2. These findings would suggest that retreatment cases included in
this study are mainly driven by reinfection as opposed to treatment failure or relapse.
Finally, based on the age distribution of TB cases in our study, recent or ongoing transmis-
sion in high burden countries is implicated as the main contributor to the TB burden rather
than disease reactivation (following longer latency periods) [47]. Additionally, an association
with young age has been used as an epidemiological proxy for highly transmissible strains and
faster rates of disease progression [48,49]. In this study, we did not detect any differences in
median age of TB patients infected with different lineages (S5 Fig), an observation that could
speak for high ongoing transmission rates in general, irrespective of lineage.
Our study is limited by focusing on a convenient collection of MTBC clinical isolates that
could be retrieved from the culture archives, representing 1.6% of all TB cases notified in 2012
and 2013. Given that our findings are based on a limited number of TB cases, the results partic-
ularly those related to associations between lineages and patients’ characteristics should be
taken with caution as the strength or lack of such associations could likely be affected by the
sampling. In addition, most of the geographical zones were underrepresented which could in
turn underestimate the respective regional lineage composition and the overall countrywide
distribution. Unfortunately, data on drug susceptibility based on other methods such as Xpert
MTB/RIF, phenotypic DST and Line Probe Assay (LPA) were unavailable, which could have
complemented the drug resistance genotyping performed on a limited subset of the retreat-
ment cases. Systematic sampling would allow for better resolution on the distribution patterns,
the frequencies and on epidemiological features of MTBC lineages, which might partially
determine the regional specific epidemics.
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In conclusion, this study addresses for the first time the countrywide MTBC population
structure based on robust SNP-typing. We show that MTBC population in Tanzania is diverse
with four of the seven known lineages detected. This study sets the stage for further in depth
investigations on epidemiological impact of MTBC lineages in Tanzania.
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